Novo Nordisk A/s Earnings

Novo Nordisk A/s’s revenue jumped 19.49% since last year same period to $78087Mn in the Q1 2025. On a quarterly growth basis, Novo Nordisk A/s has generated -8.87% fall in its revenue since last 3-months.

Novo Nordisk A/s’s net profit jumped 14.28% since last year same period to $29034Mn in the Q1 2025. On a quarterly growth basis, Novo Nordisk A/s has generated 2.85% jump in its net profits since last 3-months.

Novo Nordisk A/s’s net profit margin fell -4.37% since last year same period to 37.18% in the Q1 2025. On a quarterly growth basis, Novo Nordisk A/s has generated 12.85% jump in its net profit margins since last 3-months.

Novo Nordisk A/s’s price-to-earnings ratio after this Q1 2025 earnings stands at 20.39.

Novo Nordisk A/s’s earning per share (EPS) estimates for the current quarter stand at 0.92 - a -84.96% fall from last quarter’s estimates.

Novo Nordisk A/s’s earning per share (EPS) estimates for the current year stand at 0.92.

Novo Nordisk A/s’s earning per share (EPS) jumped 686.75% since last year same period to 6.53 in the Q1 2025. This indicates that the Novo Nordisk A/s has generated 686.75% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Novo Nordisk A/s’s return on assets (ROA) stands at 0.23.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Novo Nordisk A/s’s return on equity (ROE) stands at 0.88.

Novo Nordisk A/s declared 1.1 dividend per share during the earnings announcement for Q1 2025.